Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

In Figure 2B, an apparent “dose response” separation of the curves can be seen for those who were non-responders, and low, medium, and high responders to vitamin D replacement therapy, with the best outcomes associated with those who achieved mean D25 > 50 ng/mL.

Source: 3.3. Disease-Free Survival in the Overall Cohort. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Methods: We performed a retrospective interventional cohort study of patients with early-stage HER2-positive breast cancer treated at Cancer Treatment Centers of America Midwestern Regional Medical Center from 2008 to 2014.

Source: Abstract.

Patients were selected without risk of bias by beginning with a list of all patients treated with trastuzumab +/− pertuzumab at the institution.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

A Retrospective Interventional Study Examining Whether Successful Replacement Therapy After a Confirmed Vitamin D Deficiency Correlates with Improved Disease-Free Survival in the Curative Intent Treatment of HER2+ Breast Cancer

Cohort study · Nutrients · 2026

Original publication title

A Retrospective Interventional Study Examining Whether Successful Replacement Therapy After a Confirmed Vitamin D Deficiency Correlates with Improved Disease-Free Survival in the Curative Intent Treatment of HER2+ Breast Cancer

Eugene R. Ahn; Nandhini Iyer; Samuel B. Cothran

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The inefficiency of vitamin D repletion (60.3% success rate) in our cohort emphasizes that a fixed dose replacement strategy, even with adjustments based on serial D25 measurements, does not reliably translate into adequate repletion in real-world practice, particularly for high BMI patients [37,38,39]. To resolve this underpowering issue in future prospective studies, it would be prudent for future clinical trials to focus on interventions utilizing scientifically proven dosing formulas based on patient weight and baseline D25 [40].

As of 2026, it is currently not in the ASCO guidelines to screen and address a vitamin D deficiency in patients newly diagnosed with cancer unless they are about to start a bone weakening agent [41]; however, it is NCCN guideline-supported to screen for and treat any nutritional deficiencies concurrent with cancer treatment [42].

A total of 70.3% of Americans have a vitamin D deficiency (<30 ng/mL) [43]. Of note, our study cohort had a similar prevalence of 65.8%. Given the high pretest odds, particularly for African Americans (94.5%) and Hispanics (86.5%) and obese individuals (80.1%) [43], and that vitamin D deficiency is commonly associated with quality-of-life issues, particularly fatigue [44,45,46], routine screening and replacement therapy should be standard of care.

A total of 43% of patients newly diagnosed with cancer report fatigue before even starting their conventional anti-cancer therapies [47], and fatigue is a bidirectional predictor of poor lifestyle choices and willingness to engage with exercise or nutritional interventions [48,49,50,51]. The clinical evidence suggests that unresolved pre-treatment fatigue predicts a >3-fold risk of having more severe post-treatment fatigue [52,53], yet fatigue due to a vitamin D deficiency is one of the easiest causes of fatigue to treat [44,45,46].

One of the mechanisms of fatigue amelioration from vitamin D is enhanced skeletal muscle mitochondrial function [54,55,56]. Of note, many patients who were treated for vitamin D deficiency in our cohort only recognized their chronic fatigue symptoms after experiencing the energy improvement with their replacement therapy, as many had adapted to the deficient state for decades.

Lastly, vitamin D sufficiency likely has a protective effect on some of the toxicities associated with chemotherapy, such as paclitaxel-associated neuropathy [57,58], risk of diabetes [59,60] and impaired cognitive function [61,62,63]. Vitamin D replacement therapy is extremely well tolerated, with most experts agreeing that risk of hypercalcemia in healthy children and adults is negligible with D25 levels < 100 ng/mL [64,65,66].

Given the current state of clinical evidence, the biological plausibility of vitamin D having anti-cancer effects in ER: and HER2+ breast cancer, and the convincing evidence base that it promotes wellness and improves quality of life, it should be standard of care, until RCT evidence suggests otherwise, to screen for and treat a vitamin D deficiency in all patients with breast cancer, particularly the ER: and HER2+ subtypes. That said, prospective implementation studies are needed to verify risk/benefit in the various breast cancer subtypes, and in the context of a stressful diagnosis of breast cancer, query whether fatigue can significantly be improved with vitamin D replacement therapy and lead to better odds of healthy lifestyle changes.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Breast cancer is the most common cancer among women in the United States, with an estimated 321,910 new invasive cases and 42,140 deaths projected in 2026, accounting for nearly one-third of all new cancer diagnoses in women [1]. Breast cancer is a biologically and clinically heterogeneous disease, encompassing multiple tumor subtypes with distinct cellular and molecular features that contribute to variability in prognosis and optimal treatment options [2].

Vitamin D is a fat-soluble secosteroid that is primarily synthesized in the skin following ultraviolet light exposure, making the term “vitamin” (normally defined as a trace dietary constituent) technically a misnomer [3], although it can also be obtained from dietary and/or supplemental sources. Vitamin D serves as a precursor to the active steroid hormone 1,25-dihydroxyvitamin D (calcitriol) which subsequently binds to vitamin D receptor (VDR) and retinoic X receptor heterodimeric complex and regulates the expression of >1000 genes [4].

While rickets and the classic bony abnormalities (frontal bossing, bow leggedness) associated with a vitamin D deficiency were first reported during Europe’s industrial revolution in the mid-17th century [5], vitamin D is now recognized for its many extraskeletal functions, including but not limited to modulation of immune responses, attenuation of inflammatory pathways, and regulation of cellular proliferation and differentiation (Figure 1) [6].

Vitamin D consists of a family of two compounds, vegetable and fungal ergocalciferol (D2) and animal cholecalciferol (D3), although D3 produced by lichen is commercially available. Serum 25-hydroxyvitamin D (D25) assays typically measure both D2 and D3 variants. Normal vitamin D25 levels do not always translate to physiological sufficiency most commonly in the setting of renal failure, with rare exceptions including individuals with vitamin D-dependent rickets type IA (VDDR-1A caused by inactivating variant of CYP27B1 or 1-alpha hydroxylase) or hereditary vitamin D-resistant rickets (HVDRR caused by autosomal recessive mutations in VDR).

Also, low vitamin D25 levels do not always translate to functional deficiency, for example, in individuals with genetic polymorphisms in the vitamin D-binding protein (VDBP) particularly seen in African Americans. Lastly, patients with vitamin D-dependent rickets type IB (VDDR-IB caused by mutations in CYP2R1 or 25-hydroxylase) may not benefit from D2/D3 supplementation.

Retrospective case: control studies focused on the association of D25, currently the best practical proxy for vitamin D status, with breast cancer subtype risk [7,8], have demonstrated that a vitamin D deficiency is associated with a greater risk of higher-grade tumors and ER negative subtypes. In a meta-analysis limited to prospective cohorts [9], no statistically significant associations were found, but there was a suggestion of association with triple-negative breast cancer and distant metastases. The research connecting vitamin D deficiency with higher risk of overall cancer mortality is much stronger than breast cancer incidence [10,11].

Randomized controlled trials (RCTs) on vitamin D supplementation focused on breast cancer-specific outcomes are limited but all three have been published 2024 to 2025 and all were focused on neoadjuvant chemotherapy. Two of the three randomized clinical trials were positive and showed a doubling of the odds of pathological complete response rate (pCR) [12,13]. The third negative study enrolled 76 patients into 4 arms, resulting in a heavily underpowered study [14]. A major weakness of all three studies is that all subtypes of breast cancer were enrolled, including ER+ subtypes, and, of note, pCR has been shown to be relevant to long term prognosis in triple-negative breast cancer and ER-HER2+ breast cancer [15,16] but not so in ER+ breast cancer.

With the emergence of HER2-targeted monoclonal antibodies for the treatment of HER2+ breast cancer, it has been previously queried whether vitamin D intake might be clinically relevant in HER2+ breast cancer [17]. In this retrospective analysis of all patients receiving curative intent trastuzumab (+/− pertuzumab) at a single academic institution, there was a statistically significant improvement in disease-free survival (DFS) after multivariate analysis in those taking vitamin D supplementation (HR 0.36 p = 0.03). A weakness of the study was that D25 measurements at baseline and follow-up were not available.

At Cancer Treatment Centers of America, Midwestern Regional Medical Center (CTCA MRMC), it was standard of care to routinely screen all new patients with a D25 and follow serial measurements to assure adequate replacement was provided. Leveraging this unique clinical practice, we examined whether successful correction of vitamin D deficiency was associated with improved disease-free survival among patients with HER2-positive breast cancer.

Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Study Design and Population

We conducted a retrospective interventional cohort study of patients with HER2+ breast cancer treated at CTCA MRMC (located in the north suburbs of Chicago, i.e., Zion IL) between 2008 and 2014. The study was approved by the Institutional Review Board of CTCA MRMC.

Patients were selected without risk of bias by beginning with a list of all patients treated with trastuzumab +/− pertuzumab at the institution. Patients were included for final analysis if they had a diagnosis of early-stage HER2+ breast cancer, and continued care at CTCA for a minimum of 12 months from intake and had a baseline vitamin D deficiency, i.e., serum D25 < 30 ng/mL. The inclusion criteria were predefined in the IRB protocol before data extraction was initiated.

Histological confirmation including HER2 IHC status (3 + IHC) was done in all cases with core biopsies of the primary tumor (and if applicable, additional lymph node biopsy) before start of neoadjuvant chemotherapy or surgery, and for those with 2 + IHC equivocal results, HER2 FISH with a ratio of HER2/CEP17 greater than 2.0 would result in classification of HER2-positive status. ER or PR positivity by IHC was defined as ≥1%.

The study hypothesis was that successful vitamin D supplementation would be associated with an improved disease-free survival (DFS) using Kaplan: Meier methods. A secondary aim was to see if there was any evidence that targeting higher levels, i.e., >50 ng/mL, might have an additional benefit and to see if there was a “dose response” with higher tiers of D25 levels achieved.

2.2. Exposure Assessment and Vitamin D Responder Classification

Baseline vitamin D status was determined from an intake visit D25 (standard of care for all patients seen at CTCA MRMC prior to initial consultation). Vitamin D deficiency was defined as a baseline D25 < 30 ng/mL. Patients who were vitamin D-deficient at baseline received vitamin D supplementation (most commonly D3, but if patient preferred D2 it was allowed, and generally USP certified brands were preferred) as part of routine clinical care through consultation with a naturopath (also standard of care) and the medical oncology team.

Although a formal protocol for replacement was not defined by the institution, starting replacement doses ranged from 2000 to 10,000 IU/d D3 and were adjusted accordingly based on subsequent D25 measurements.

The D25 assay was done in-house utilizing the Roche Cobas 6000 vitamin D total assay, an automated chemiluminescent immunoassay. The system employs VDBP labeled with a ruthenium complex as capture protein to bind 25-hydroxyvitamin D3 and D2. Cross-reactivity to 24,25-dihydroxyvitamin D is blocked by a specific monoclonal antibody.

The primary exposure of interest was response to vitamin D supplementation. Among patients with baseline vitamin D deficiency, a response was determined from the mean D25 concentration measured after the intake assessment through the end of the first year (to mirror the typical duration of HER2-targeted therapy). Patients were classified as responders if the mean follow-up D25 level was ≥30 ng/mL and as non-responders if the mean D25 remained <30 ng/mL. Responders were further stratified into low (30 to 40 ng/mL), medium (40 to 50 ng/mL), and high (>50 ng/mL) responder categories.

2.3. Outcomes

The primary outcome was disease-free survival (DFS). DFS was defined as the interval from the date of initiation of neoadjuvant therapy or definitive surgery, whichever occurred first, to the earliest documented disease recurrence, development of metastatic disease, or death from any cause. Patients without disease progression were censored at the date of last clinical follow-up.

2.4. Covariates

Clinical and pathologic covariates of interest included age at diagnosis, body mass index (BMI), estrogen receptor (ER) status, progesterone receptor (PR) status, tumor size, number of metastatic lymph nodes, presence of lymphovascular invasion, type of chemotherapy (neoadjuvant vs. adjuvant), use of pertuzumab, type of definitive surgery, and receipt of radiation therapy.

2.5. Statistical Analysis

Baseline patient characteristics were summarized using frequencies and percentages for categorical variables and appropriate measures of central tendency for continuous variables. Differences across groups were assessed using standard comparative statistical methods, as appropriate.

DFS was estimated using the Kaplan: Meier method, and survival curves were compared using the log-rank test. Univariate Cox proportional hazards regression models were first used to assess the association between individual covariates and DFS. Variables demonstrating clinical or statistical relevance were subsequently included in multivariable Cox proportional hazards models to evaluate independent associations after adjustment for potential confounders. Effect estimates were reported as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs).

The proportional hazards assumption was evaluated using both graphical methods, including log-minus-log plots for categorical variables, and statistical testing through extended Cox models incorporating time-dependent covariates for continuous variables. A two-sided p-value ≤ 0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics, version 28.0 (IBM Corp., Armonk, NY, USA).

Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods

Results: Study Cohort and Baseline Characteristics

A total of 196 patients met the initial eligibility criteria and were then subcategorized into vitamin D sufficiency or deficiency status at baseline. Baseline demographic and clinicopathologic characteristics are summarized in Table 1. Of the 196 patients eligible for analysis, 129 patients (65.8%) had deficient D25 levels (<30 ng/mL), while 67 patients (34.2%) had sufficient levels (≥30 ng/mL).

Nearly half of the patients had a body mass index (BMI) > 30 kg/m2 (44.9%). Most patients were White (66.3%), followed by African American (21.4%) and Hispanic (7.7%). Most tumors measured <2 cm (64.1%), and 55.7% of patients had no metastatic lymph node involvement. Lymphovascular invasion was present in 36.2% of cases.

Hormone receptor positivity was common, with estrogen receptor (ER) positivity in 70.5% and progesterone receptor (PR) positivity in 53.4% of patients. Approximately half of the cohort received neoadjuvant chemotherapy (49.5%), while the rest received adjuvant chemotherapy (50.5%). Definitive surgery consisted predominantly of mastectomy (56.9%), and most patients received adjuvant radiation therapy (73.5%). Pertuzumab was used in 50% of patients.

Table 1

Baseline demographics and characteristics.

VariablesN (%)
Baseline Vitamin D
        <30 ng/mL129 (65.8)
        ≥30 ng/mL67 (34.2)
Age at diagnosis
        <50 years101 (51.5)
        ≥50 years95 (48.5)
BMI
        <30 kg/m2108 (55.1)
        ≥30 kg/m288 (44.9)
Race
        White130 (66.3)
        African American42 (21.4)
        Hispanic15 (7.7)
        Others9 (4.6)
Tumor size
        <2 cm123 (64.1)
        ≥2 cm69 (35.9)
        Unknown4
Number of metastatic lymph nodes
        0108 (55.7)
        ≥186 (44.3)
        Unknown2
Lymphovascular invasion
        No104 (63.8)
        Yes59 (36.2)
        Unknown33
ER status
        Negative56 (29.5)
        Positive134 (70.5)
        Unknown6
PR status
        Negative89 (46.6)
        Positive102 (53.4)
        Unknown5
Type of chemotherapy
        Neoadjuvant97 (49.5)
        Adjuvant99 (50.5)
Definitive Surgery
        Lumpectomy84 (43.1)
        Mastectomy111 (56.9)
        Unknown1
Radiation therapy
        No52 (26.5)
        Yes144 (73.5)
Pertuzumab
        No98 (50)
        Yes98 (50)
Disease progression
        No165 (84.2)
        Yes31 (15.8)
Vitamin D response after supplementation
        Responders76 (60.3)
        low27
        medium31
        high18
        Non-responders50 (39.7)
        Unknown3
Source: 3.1. Study Cohort and Baseline Characteristics Source: 3.1. Study Cohort and Baseline Characteristics Source: 3.1. Study Cohort and Baseline Characteristics Source: 3.1. Study Cohort and Baseline Characteristics

Baseline Vitamin D Status and Response to Supplementation

Results: Baseline Vitamin D Status and Response to Supplementation

Among the 129 patients who were vitamin D-deficient at baseline, 76 patients (60.3%) achieved adequate vitamin D repletion (defined by mean D25 > 30 ng/mL in the first year of follow-up) and were classified as responders, while 50 patients (39.7%) remained below the target threshold and were classified as non-responders. Vitamin D response status could not be determined for three patients due to incomplete follow-up laboratory data and were not included for analysis. Among the 76 responders, 27 patients were classified as low responders (mean follow-up D25 level 30 to 40 ng/mL), 31 medium responders (40 to 50 ng/mL), and 18 high responders (>50 ng/mL).

Source: 3.2. Baseline Vitamin D Status and Response to Supplementation

Results: Disease-Free Survival in the Overall Cohort

During follow-up, 31 of 196 patients (15.8%) experienced a disease-free survival (DFS) event. No deaths were recorded, so overall survival analysis was not possible, and in essence, DFS in this cohort would be accurately reframed as recurrence-free survival (RFS). Owing to the relatively low number of disease recurrence events, the median DFS was not reached. The mean DFS for the overall cohort was 10.2 years (95% confidence interval [CI], 9.58 to 10.83). The estimated 3-year DFS rate for the entire cohort was 88%, with non-responders having an 85% 3 yr DFS and responders having a 90% 3 yr DFS, as shown in Figure 2A.

In Figure 2B, an apparent “dose response” separation of the curves can be seen for those who were non-responders, and low, medium, and high responders to vitamin D replacement therapy, with the best outcomes associated with those who achieved mean D25 > 50 ng/mL.

Source: 3.3. Disease-Free Survival in the Overall Cohort Source: 3.3. Disease-Free Survival in the Overall Cohort

Results: Cox Proportional Hazards Analysis

Univariate and multivariable Cox proportional hazards regression analyses were performed to identify factors associated with DFS. See Table 2 for Univariate Cox Proportional Hazard Analysis. In univariate analyses, BMI, lymphovascular invasion, treatment sequence, and pertuzumab use were significantly associated with DFS. Patients with BMI ≥ 30 kg/m2 surprisingly demonstrated a lower hazard of disease progression compared with those with BMI < 30 kg/m2 (HR 0.41 p = 0.03). The presence of lymphovascular invasion was associated with a higher hazard of disease progression (HR 2.30, p = 0.04).

Patients treated in the neoadjuvant setting versus adjuvant (only) exhibited a higher hazard of disease progression (HR 3.80 p = 0.001) as well as those who received pertuzumab (HR 2.50 p = 0.02), likely due to selection bias of more advanced stage presentations.

DFS did not differ significantly by age at diagnosis, i.e., ≥50 years versus < 50 (HR 1.1 p = 0.7), race, i.e., non-White subjects versus White subjects (HR 1.3, p = 0.3), tumor size, i.e., ≥2 cm vs. <2 cm (HR 1.3 p = 0.3), nodal status, i.e., ≥1 metastatic versus 0 lymph nodes (HR 1.4 p = 0.3), estrogen receptor status, i.e., positive versus negative (HR 0.79 p = 0.5), progesterone receptor status, i.e., positive versus negative (HR 0.81 p = 0.6), nor baseline vitamin D25 status, i.e., <30 ng/mL versus > 30 ng/mL (HR 0.76 p = 0.45).

Although a binary analysis of White vs. non-White ethnicity was not significant, African Americans continued to have the worst 3 yr DFS of 79%, compared to 89% for White subjects and 100% for Hispanics.

When using vitamin D responders as reference, vitamin D non-responders had a HR of 1.7 for worse DFS, although the p-value was not significant p = 0.23.

Multivariable Cox proportional hazards regression (Table 3) was subsequently performed to evaluate independent associations with DFS after adjustment for BMI, lymphovascular invasion, treatment sequence, and pertuzumab use. In the adjusted model, lymphovascular invasion remained independently associated with worse DFS (HR 2.3 p = 0.05). Treatment sequence also remained independently associated with DFS, with neoadjuvant therapy associated with a higher hazard of disease progression compared with adjuvant therapy (HR 4.0 p = 0.008). After adjustment, BMI ≥ 30 kg/m2 continued to demonstrate a sizable lower hazard of disease progression compared with BMI < 30 kg/m2 with HR 0.46; however, it lost its statistical significance (p = 0.09).

Pertuzumab use was not independently associated with DFS (HR 1.20 p = 0.69).

Table 2

Univariate Cox proportional hazard analysis (* reflects statistical significance achieved).

VariablesHazard Ratio95% CIp-Value
Vitamin D response after supplementation
        Responders (reference)
        Non-responders1.70.71 to 4.30.23
Vitamin D response after supplementation
        High responders (reference)
        Medium responders1.40.26 to 7.80.69
        Low responders1.10.19 to 6.80.89
        Non-responders2.10.46 to 9.60.34
Baseline Vitamin D
        >=30 ng/mL (reference)
        <30 ng/mL0.760.37 to 1.60.45
Age at diagnosis
        <50 years (reference)
        >=50 years1.10.56 to 2.30.73
BMI
        <30 kg/m2 (reference)
        >=30 kg/m20.410.18 to 0.910.03 *
Race
        White (reference)
        Others1.30.62 to 2.60.50
Tumor size
        <2 cm (reference)
        >=2 cm1.30.64 to 2.80.44
Number of metastatic lymph nodes
        0 (reference)
        >=11.40.69 to 2.90.33
Lymphovascular invasion
        No (reference)
        Yes2.31.03 to 5.30.04 *
ER status
        Negative (reference)
        Positive0.790.37 to 1.70.53
PR status
        Negative (reference)
        Positive0.810.40 to 1.70.57
Type of chemotherapy
        Adjuvant (reference)
        Neoadjuvant3.81.7 to 8.70.001 *
Definitive Surgery
        Lumpectomy (reference)
        Mastectomy1.50.72 to 3.20.28
Radiation therapy
        No (reference)
        Yes1.40.58 to 3.50.44
Pertuzumab
        No (reference)
        Yes2.51.2 to 5.50.02 *
Nuclear grade
        1 or 2 (reference)
        31.40.59 to 3.50.43
Table 3

Multivariate Cox regression analysis (* reflects statistical significance achieved).

VariablesHazard Ratio95% CIp-Value
BMI
        <30 kg/m2 (reference)
        ≥30 kg/m20.460.18 to 1.10.09
Lymphovascular invasion
        No (reference)
        Yes2.31.01 to 5.40.05 *
Type of chemotherapy
        Adjuvant (reference)
        Neoadjuvant4.01.4 to 11.30.008 *
Pertuzumab
        No (reference)
        Yes1.20.45 to 3.40.07
Source: 3.4. Cox Proportional Hazards Analysis Source: 3.4. Cox Proportional Hazards Analysis Source: 3.4. Cox Proportional Hazards Analysis Source: 3.4. Cox Proportional Hazards Analysis Source: 3.4. Cox Proportional Hazards Analysis Source: 3.4. Cox Proportional Hazards Analysis Source: 3.4. Cox Proportional Hazards Analysis

Discussion: Limitations and Additional Strengths

Some of the limitations of this study include it being retrospective, single-institution, and likely underpowered. The underpowering due to low frequency of DFS events is likely multifactorial. First, it is unusual to have a HER2+ breast cancer cohort where nearly two-thirds of the tumors are <2.0 cm. Second, the majority of the HER2+ breast cancer cases were not of the ER-HER2+ subtype (70.5% were ER+). We still included this subset because, unlike the neoadjuvant studies above, our study period was not limited to neoadjuvant therapy and was inclusive of adjuvant therapy when patients were receiving antiestrogen therapy with trastuzumab +/− pertuzumab.

However, ER+HER2+ breast cancer has a better prognosis than ER-HER2+ breast cancer and has outcomes approaching luminal tumors [18]. This underpowering increases the risk that these findings were by chance.

Other study weaknesses include the study definition of exposure and the requirement of follow-up of D25 levels in the subsequent year without specification of the intervals for testing D25 and without a more specified standardized replacement protocol based on BMI. For example, patients who were “responders” might have been generally more compliant with conventional therapy and had better prognosis as a result and “non-responders” might have had overlap with socioeconomic difficulties as a confounder, had less frequent D25 tests done and had less efficient dose adjustments over the first year.

Lack of sufficient doses given to high BMI patients also likely underpowered the study. Vitamin D replacement treatment heterogeneity based on different clinician preferences might have created additional confounding variables.

Since we included both patients receiving neoadjuvant therapy and patients receiving adjuvant therapy, we did introduce more conventional treatment heterogeneity and our multivariate analysis did show that those who received neoadjuvant chemotherapy had a 4-fold worse prognosis (p = 0.008) due to selection of more advanced stages, and pertuzumab use nearly was significant (p = 0.07), as pertuzumab is indicated in patients with more advanced stages. These additional confounders also limit the generalizability of the findings.

Lastly, although none of the patients in this cohort had renal failure or were on dialysis, a formal assessment and categorization of renal insufficiency was not performed, which theoretically could have influenced results, since in such patients D25 levels might not have accurately reflected bioactive vitamin D due to impaired activation of D25 in the renal tubules.

A strength is that the patient population queried was more diverse and representative of a typical American population compared to those enrolled in previous RCTs, with a greater proportion of obese patients (44.9% > 30 kg/m2) and ethnic minorities, including African Americans (21.4%) and Hispanics (7.7%).

Source: 4.1. Limitations and Additional Strengths Source: 4.1. Limitations and Additional Strengths Source: 4.1. Limitations and Additional Strengths Source: 4.1. Limitations and Additional Strengths Source: 4.1. Limitations and Additional Strengths

Review of Putative Mechanisms of Vitamin D Bioactivity in HER2+ Breast Cancer

Discussion: Review of Putative Mechanisms of Vitamin D Bioactivity in HER2+ Breast Cancer

Although our study did not query molecular insights into the reason for potential biological activity, it is important to review the large evidence base supporting the biological plausibility of such activity.

Vitamin D is a steroid prohormone and requires sequential hydroxylation to become biologically active, with both renal and extrarenal tissues, including breast epithelium, capable of activating circulating 25-hydroxyvitamin D to 1,25-hydroxyvitamin D or calcitriol [27]. Calcitriol signaling through the vitamin D receptor (VDR) influences multiple cancer-relevant pathways, including the inhibition of cellular proliferation via cell-cycle arrest, the induction of apoptosis through the modulation of Bcl-2 family proteins, the inhibition of matrix metalloproteinases involved in tumor progression, the downregulation of COX-2 expression and associated inflammation, and the suppression of additional invasive and angiogenic processes [6,27].

Recent evidence shows that vitamin D stimulation of intestinal VDR induces an improved microbiome and subsequent anti-tumor immunity in mouse models [28].

Vitamin D has been shown to enhance NK cell activity, providing a mechanism by which vitamin D might be particularly beneficial in HER2+ breast cancer treated in the post-trastuzumab era [29]. Preclinical models looking at another monoclonal antibody rituximab for lymphoma identified that maximal NK cell activity was observed at 65 ng/mL, supporting our findings that high responders, D25 levels > 50 ng/mL, had the best nominal DFS. Preclinical studies suggest vitamin D analogs may inhibit HER2-associated downstream signaling pathways, including the ERK and PI3K/AKT cascades [30,31]

Another potential mechanism for the biological activity of vitamin D in HER2+ breast cancer (and ER: breast cancer) is the known cross-talk between TP53 and VDR [32]. HER2+ breast cancer has a high prevalence of TP53 mutations, 55 to 75% [33], and patients with germline TP53 mutations are more likely to develop HER2+ breast cancer (67%) versus other subtypes [34]. In a subset analysis of TP53 mutated gastrointestinal cancers (using p53 immunoreactivity as a proxy) in the AMATERASU study [35], vitamin D supplementation led to 81% 5-year relapse free survival versus 31% in the placebo group (HR 0.27 95% CI 0.11 to 0.61), suggesting TP53 mutations might be an important biomarker for cancers more likely to benefit from vitamin D supplementation [36].

Source: 4.3. Review of Putative Mechanisms of Vitamin D Bioactivity in HER2+ Breast Cancer Source: 4.3. Review of Putative Mechanisms of Vitamin D Bioactivity in HER2+ Breast Cancer Source: 4.3. Review of Putative Mechanisms of Vitamin D Bioactivity in HER2+ Breast Cancer Source: 4.3. Review of Putative Mechanisms of Vitamin D Bioactivity in HER2+ Breast Cancer

Results

3.1. Study Cohort and Baseline Characteristics

A total of 196 patients met the initial eligibility criteria and were then subcategorized into vitamin D sufficiency or deficiency status at baseline. Baseline demographic and clinicopathologic characteristics are summarized in Table 1. Of the 196 patients eligible for analysis, 129 patients (65.8%) had deficient D25 levels (<30 ng/mL), while 67 patients (34.2%) had sufficient levels (≥30 ng/mL).

Nearly half of the patients had a body mass index (BMI) > 30 kg/m2 (44.9%). Most patients were White (66.3%), followed by African American (21.4%) and Hispanic (7.7%). Most tumors measured <2 cm (64.1%), and 55.7% of patients had no metastatic lymph node involvement. Lymphovascular invasion was present in 36.2% of cases.

Hormone receptor positivity was common, with estrogen receptor (ER) positivity in 70.5% and progesterone receptor (PR) positivity in 53.4% of patients. Approximately half of the cohort received neoadjuvant chemotherapy (49.5%), while the rest received adjuvant chemotherapy (50.5%). Definitive surgery consisted predominantly of mastectomy (56.9%), and most patients received adjuvant radiation therapy (73.5%). Pertuzumab was used in 50% of patients.

3.2. Baseline Vitamin D Status and Response to Supplementation

Among the 129 patients who were vitamin D-deficient at baseline, 76 patients (60.3%) achieved adequate vitamin D repletion (defined by mean D25 > 30 ng/mL in the first year of follow-up) and were classified as responders, while 50 patients (39.7%) remained below the target threshold and were classified as non-responders. Vitamin D response status could not be determined for three patients due to incomplete follow-up laboratory data and were not included for analysis. Among the 76 responders, 27 patients were classified as low responders (mean follow-up D25 level 30 to 40 ng/mL), 31 medium responders (40 to 50 ng/mL), and 18 high responders (>50 ng/mL).

3.3. Disease-Free Survival in the Overall Cohort

During follow-up, 31 of 196 patients (15.8%) experienced a disease-free survival (DFS) event. No deaths were recorded, so overall survival analysis was not possible, and in essence, DFS in this cohort would be accurately reframed as recurrence-free survival (RFS). Owing to the relatively low number of disease recurrence events, the median DFS was not reached. The mean DFS for the overall cohort was 10.2 years (95% confidence interval [CI], 9.58 to 10.83). The estimated 3-year DFS rate for the entire cohort was 88%, with non-responders having an 85% 3 yr DFS and responders having a 90% 3 yr DFS, as shown in Figure 2A.

In Figure 2B, an apparent “dose response” separation of the curves can be seen for those who were non-responders, and low, medium, and high responders to vitamin D replacement therapy, with the best outcomes associated with those who achieved mean D25 > 50 ng/mL.

3.4. Cox Proportional Hazards Analysis

Univariate and multivariable Cox proportional hazards regression analyses were performed to identify factors associated with DFS. See Table 2 for Univariate Cox Proportional Hazard Analysis. In univariate analyses, BMI, lymphovascular invasion, treatment sequence, and pertuzumab use were significantly associated with DFS. Patients with BMI ≥ 30 kg/m2 surprisingly demonstrated a lower hazard of disease progression compared with those with BMI < 30 kg/m2 (HR 0.41 p = 0.03). The presence of lymphovascular invasion was associated with a higher hazard of disease progression (HR 2.30, p = 0.04).

Patients treated in the neoadjuvant setting versus adjuvant (only) exhibited a higher hazard of disease progression (HR 3.80 p = 0.001) as well as those who received pertuzumab (HR 2.50 p = 0.02), likely due to selection bias of more advanced stage presentations.

DFS did not differ significantly by age at diagnosis, i.e., ≥50 years versus < 50 (HR 1.1 p = 0.7), race, i.e., non-White subjects versus White subjects (HR 1.3, p = 0.3), tumor size, i.e., ≥2 cm vs. <2 cm (HR 1.3 p = 0.3), nodal status, i.e., ≥1 metastatic versus 0 lymph nodes (HR 1.4 p = 0.3), estrogen receptor status, i.e., positive versus negative (HR 0.79 p = 0.5), progesterone receptor status, i.e., positive versus negative (HR 0.81 p = 0.6), nor baseline vitamin D25 status, i.e., <30 ng/mL versus > 30 ng/mL (HR 0.76 p = 0.45).

Although a binary analysis of White vs. non-White ethnicity was not significant, African Americans continued to have the worst 3 yr DFS of 79%, compared to 89% for White subjects and 100% for Hispanics.

When using vitamin D responders as reference, vitamin D non-responders had a HR of 1.7 for worse DFS, although the p-value was not significant p = 0.23.

Multivariable Cox proportional hazards regression (Table 3) was subsequently performed to evaluate independent associations with DFS after adjustment for BMI, lymphovascular invasion, treatment sequence, and pertuzumab use. In the adjusted model, lymphovascular invasion remained independently associated with worse DFS (HR 2.3 p = 0.05). Treatment sequence also remained independently associated with DFS, with neoadjuvant therapy associated with a higher hazard of disease progression compared with adjuvant therapy (HR 4.0 p = 0.008). After adjustment, BMI ≥ 30 kg/m2 continued to demonstrate a sizable lower hazard of disease progression compared with BMI < 30 kg/m2 with HR 0.46; however, it lost its statistical significance (p = 0.09).

Pertuzumab use was not independently associated with DFS (HR 1.20 p = 0.69).

Table 1

Baseline demographics and characteristics.

VariablesN (%)
Baseline Vitamin D
        <30 ng/mL129 (65.8)
        ≥30 ng/mL67 (34.2)
Age at diagnosis
        <50 years101 (51.5)
        ≥50 years95 (48.5)
BMI
        <30 kg/m2108 (55.1)
        ≥30 kg/m288 (44.9)
Race
        White130 (66.3)
        African American42 (21.4)
        Hispanic15 (7.7)
        Others9 (4.6)
Tumor size
        <2 cm123 (64.1)
        ≥2 cm69 (35.9)
        Unknown4
Number of metastatic lymph nodes
        0108 (55.7)
        ≥186 (44.3)
        Unknown2
Lymphovascular invasion
        No104 (63.8)
        Yes59 (36.2)
        Unknown33
ER status
        Negative56 (29.5)
        Positive134 (70.5)
        Unknown6
PR status
        Negative89 (46.6)
        Positive102 (53.4)
        Unknown5
Type of chemotherapy
        Neoadjuvant97 (49.5)
        Adjuvant99 (50.5)
Definitive Surgery
        Lumpectomy84 (43.1)
        Mastectomy111 (56.9)
        Unknown1
Radiation therapy
        No52 (26.5)
        Yes144 (73.5)
Pertuzumab
        No98 (50)
        Yes98 (50)
Disease progression
        No165 (84.2)
        Yes31 (15.8)
Vitamin D response after supplementation
        Responders76 (60.3)
        low27
        medium31
        high18
        Non-responders50 (39.7)
        Unknown3
Table 2

Univariate Cox proportional hazard analysis (* reflects statistical significance achieved).

VariablesHazard Ratio95% CIp-Value
Vitamin D response after supplementation
        Responders (reference)
        Non-responders1.70.71 to 4.30.23
Vitamin D response after supplementation
        High responders (reference)
        Medium responders1.40.26 to 7.80.69
        Low responders1.10.19 to 6.80.89
        Non-responders2.10.46 to 9.60.34
Baseline Vitamin D
        >=30 ng/mL (reference)
        <30 ng/mL0.760.37 to 1.60.45
Age at diagnosis
        <50 years (reference)
        >=50 years1.10.56 to 2.30.73
BMI
        <30 kg/m2 (reference)
        >=30 kg/m20.410.18 to 0.910.03 *
Race
        White (reference)
        Others1.30.62 to 2.60.50
Tumor size
        <2 cm (reference)
        >=2 cm1.30.64 to 2.80.44
Number of metastatic lymph nodes
        0 (reference)
        >=11.40.69 to 2.90.33
Lymphovascular invasion
        No (reference)
        Yes2.31.03 to 5.30.04 *
ER status
        Negative (reference)
        Positive0.790.37 to 1.70.53
PR status
        Negative (reference)
        Positive0.810.40 to 1.70.57
Type of chemotherapy
        Adjuvant (reference)
        Neoadjuvant3.81.7 to 8.70.001 *
Definitive Surgery
        Lumpectomy (reference)
        Mastectomy1.50.72 to 3.20.28
Radiation therapy
        No (reference)
        Yes1.40.58 to 3.50.44
Pertuzumab
        No (reference)
        Yes2.51.2 to 5.50.02 *
Nuclear grade
        1 or 2 (reference)
        31.40.59 to 3.50.43
Table 3

Multivariate Cox regression analysis (* reflects statistical significance achieved).

VariablesHazard Ratio95% CIp-Value
BMI
        <30 kg/m2 (reference)
        ≥30 kg/m20.460.18 to 1.10.09
Lymphovascular invasion
        No (reference)
        Yes2.31.01 to 5.40.05 *
Type of chemotherapy
        Adjuvant (reference)
        Neoadjuvant4.01.4 to 11.30.008 *
Pertuzumab
        No (reference)
        Yes1.20.45 to 3.40.07
Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results

Conclusions

The inefficiency of vitamin D repletion (60.3% success rate) in our cohort emphasizes that a fixed dose replacement strategy, even with adjustments based on serial D25 measurements, does not reliably translate into adequate repletion in real-world practice, particularly for high BMI patients [37,38,39]. To resolve this underpowering issue in future prospective studies, it would be prudent for future clinical trials to focus on interventions utilizing scientifically proven dosing formulas based on patient weight and baseline D25 [40].

As of 2026, it is currently not in the ASCO guidelines to screen and address a vitamin D deficiency in patients newly diagnosed with cancer unless they are about to start a bone weakening agent [41]; however, it is NCCN guideline-supported to screen for and treat any nutritional deficiencies concurrent with cancer treatment [42].

A total of 70.3% of Americans have a vitamin D deficiency (<30 ng/mL) [43]. Of note, our study cohort had a similar prevalence of 65.8%. Given the high pretest odds, particularly for African Americans (94.5%) and Hispanics (86.5%) and obese individuals (80.1%) [43], and that vitamin D deficiency is commonly associated with quality-of-life issues, particularly fatigue [44,45,46], routine screening and replacement therapy should be standard of care.

A total of 43% of patients newly diagnosed with cancer report fatigue before even starting their conventional anti-cancer therapies [47], and fatigue is a bidirectional predictor of poor lifestyle choices and willingness to engage with exercise or nutritional interventions [48,49,50,51]. The clinical evidence suggests that unresolved pre-treatment fatigue predicts a >3-fold risk of having more severe post-treatment fatigue [52,53], yet fatigue due to a vitamin D deficiency is one of the easiest causes of fatigue to treat [44,45,46].

One of the mechanisms of fatigue amelioration from vitamin D is enhanced skeletal muscle mitochondrial function [54,55,56]. Of note, many patients who were treated for vitamin D deficiency in our cohort only recognized their chronic fatigue symptoms after experiencing the energy improvement with their replacement therapy, as many had adapted to the deficient state for decades.

Lastly, vitamin D sufficiency likely has a protective effect on some of the toxicities associated with chemotherapy, such as paclitaxel-associated neuropathy [57,58], risk of diabetes [59,60] and impaired cognitive function [61,62,63]. Vitamin D replacement therapy is extremely well tolerated, with most experts agreeing that risk of hypercalcemia in healthy children and adults is negligible with D25 levels < 100 ng/mL [64,65,66].

Given the current state of clinical evidence, the biological plausibility of vitamin D having anti-cancer effects in ER: and HER2+ breast cancer, and the convincing evidence base that it promotes wellness and improves quality of life, it should be standard of care, until RCT evidence suggests otherwise, to screen for and treat a vitamin D deficiency in all patients with breast cancer, particularly the ER: and HER2+ subtypes. That said, prospective implementation studies are needed to verify risk/benefit in the various breast cancer subtypes, and in the context of a stressful diagnosis of breast cancer, query whether fatigue can significantly be improved with vitamin D replacement therapy and lead to better odds of healthy lifestyle changes.

Source: 5. Conclusions Source: 5. Conclusions Source: 5. Conclusions Source: 5. Conclusions Source: 5. Conclusions Source: 5. Conclusions
Authors’ abstract

Background: Vitamin D is a secosteroid that exerts immunomodulatory and anti-proliferative effects through the vitamin D receptor (VDR). Because HER2-targeted therapies substantially improve prognosis in HER2-positive breast cancer and introduces a new mechanism of immunotherapy, we hypothesized that successful correction of vitamin D deficiency would be associated with improved disease-free survival (DFS) in patients treated with curative intent. Methods: We performed a retrospective interventional cohort study of patients with early-stage HER2-positive breast cancer treated at Cancer Treatment Centers of America Midwestern Regional Medical Center from 2008 to 2014.

Eligible patients had baseline vitamin D deficiency (25-hydroxyvitamin D or D25 < 30 ng/mL), received trastuzumab-based therapy, and had ≥12 months follow-up. Patients received vitamin D3 supplementation (typically 2000 to 10,000 IU/day) with doses adjusted based on D25 level follow-up. Responders were defined as having achieved a mean D25 ≥ 30 ng/mL during the first year; non-responders remained <30 ng/mL DFS was analyzed using Kaplan: Meier and Cox models. Results: Of 196 patients, 129 (65.8%) were vitamin D-deficient at baseline. Among these, 76 (60.3%) achieved repletion while 50 (39.7%) remained deficient.

Three did not have D25 follow-up obtained. Thirty-one DFS events occurred but no deaths. Responders demonstrated numerically improved outcomes (3-year DFS 90% vs. 85%). Non-responders had a 1.7-fold higher hazard of recurrence, and those who achieved the highest D25 levels (>50 ng/mL) had the most favorable DFS trends, suggesting a dose response. Conclusions: Failure to correct a vitamin D deficiency was associated with a 1.7-fold higher recurrence risk, although the relationship did not achieve statistical significance. A similar effect size was reported in another retrospective cohort of HER2-positive breast cancer that did achieve statistical significance, and a doubling of pCR rates was seen in two recently completed RCTs in 2025, with benefits particularly seen in the triple-negative and HER2-positive subtypes.

Prospective trials evaluating optimized vitamin D repletion in HER2-positive breast cancer are warranted.

Read the full paper

1. Introduction

Breast cancer is the most common cancer among women in the United States, with an estimated 321,910 new invasive cases and 42,140 deaths projected in 2026, accounting for nearly one-third of all new cancer diagnoses in women [1]. Breast cancer is a biologically and clinically heterogeneous disease, encompassing multiple tumor subtypes with distinct cellular and molecular features that contribute to variability in prognosis and optimal treatment options [2].

Vitamin D is a fat-soluble secosteroid that is primarily synthesized in the skin following ultraviolet light exposure, making the term “vitamin” (normally defined as a trace dietary constituent) technically a misnomer [3], although it can also be obtained from dietary and/or supplemental sources. Vitamin D serves as a precursor to the active steroid hormone 1,25-dihydroxyvitamin D (calcitriol) which subsequently binds to vitamin D receptor (VDR) and retinoic X receptor heterodimeric complex and regulates the expression of >1000 genes [4].

While rickets and the classic bony abnormalities (frontal bossing, bow leggedness) associated with a vitamin D deficiency were first reported during Europe’s industrial revolution in the mid-17th century [5], vitamin D is now recognized for its many extraskeletal functions, including but not limited to modulation of immune responses, attenuation of inflammatory pathways, and regulation of cellular proliferation and differentiation (Figure 1) [6].

Vitamin D consists of a family of two compounds, vegetable and fungal ergocalciferol (D2) and animal cholecalciferol (D3), although D3 produced by lichen is commercially available. Serum 25-hydroxyvitamin D (D25) assays typically measure both D2 and D3 variants. Normal vitamin D25 levels do not always translate to physiological sufficiency most commonly in the setting of renal failure, with rare exceptions including individuals with vitamin D-dependent rickets type IA (VDDR-1A caused by inactivating variant of CYP27B1 or 1-alpha hydroxylase) or hereditary vitamin D-resistant rickets (HVDRR caused by autosomal recessive mutations in VDR).

Also, low vitamin D25 levels do not always translate to functional deficiency, for example, in individuals with genetic polymorphisms in the vitamin D-binding protein (VDBP) particularly seen in African Americans. Lastly, patients with vitamin D-dependent rickets type IB (VDDR-IB caused by mutations in CYP2R1 or 25-hydroxylase) may not benefit from D2/D3 supplementation.

Retrospective case: control studies focused on the association of D25, currently the best practical proxy for vitamin D status, with breast cancer subtype risk [7,8], have demonstrated that a vitamin D deficiency is associated with a greater risk of higher-grade tumors and ER negative subtypes. In a meta-analysis limited to prospective cohorts [9], no statistically significant associations were found, but there was a suggestion of association with triple-negative breast cancer and distant metastases. The research connecting vitamin D deficiency with higher risk of overall cancer mortality is much stronger than breast cancer incidence [10,11].

Randomized controlled trials (RCTs) on vitamin D supplementation focused on breast cancer-specific outcomes are limited but all three have been published 2024 to 2025 and all were focused on neoadjuvant chemotherapy. Two of the three randomized clinical trials were positive and showed a doubling of the odds of pathological complete response rate (pCR) [12,13]. The third negative study enrolled 76 patients into 4 arms, resulting in a heavily underpowered study [14]. A major weakness of all three studies is that all subtypes of breast cancer were enrolled, including ER+ subtypes, and, of note, pCR has been shown to be relevant to long term prognosis in triple-negative breast cancer and ER-HER2+ breast cancer [15,16] but not so in ER+ breast cancer.

With the emergence of HER2-targeted monoclonal antibodies for the treatment of HER2+ breast cancer, it has been previously queried whether vitamin D intake might be clinically relevant in HER2+ breast cancer [17]. In this retrospective analysis of all patients receiving curative intent trastuzumab (+/− pertuzumab) at a single academic institution, there was a statistically significant improvement in disease-free survival (DFS) after multivariate analysis in those taking vitamin D supplementation (HR 0.36 p = 0.03). A weakness of the study was that D25 measurements at baseline and follow-up were not available.

At Cancer Treatment Centers of America, Midwestern Regional Medical Center (CTCA MRMC), it was standard of care to routinely screen all new patients with a D25 and follow serial measurements to assure adequate replacement was provided. Leveraging this unique clinical practice, we examined whether successful correction of vitamin D deficiency was associated with improved disease-free survival among patients with HER2-positive breast cancer.

2. Materials and Methods

2.1. Study Design and Population

We conducted a retrospective interventional cohort study of patients with HER2+ breast cancer treated at CTCA MRMC (located in the north suburbs of Chicago, i.e., Zion IL) between 2008 and 2014. The study was approved by the Institutional Review Board of CTCA MRMC.

Patients were selected without risk of bias by beginning with a list of all patients treated with trastuzumab +/− pertuzumab at the institution. Patients were included for final analysis if they had a diagnosis of early-stage HER2+ breast cancer, and continued care at CTCA for a minimum of 12 months from intake and had a baseline vitamin D deficiency, i.e., serum D25 < 30 ng/mL. The inclusion criteria were predefined in the IRB protocol before data extraction was initiated.

Histological confirmation including HER2 IHC status (3 + IHC) was done in all cases with core biopsies of the primary tumor (and if applicable, additional lymph node biopsy) before start of neoadjuvant chemotherapy or surgery, and for those with 2 + IHC equivocal results, HER2 FISH with a ratio of HER2/CEP17 greater than 2.0 would result in classification of HER2-positive status. ER or PR positivity by IHC was defined as ≥1%.

The study hypothesis was that successful vitamin D supplementation would be associated with an improved disease-free survival (DFS) using Kaplan: Meier methods. A secondary aim was to see if there was any evidence that targeting higher levels, i.e., >50 ng/mL, might have an additional benefit and to see if there was a “dose response” with higher tiers of D25 levels achieved.

2.2. Exposure Assessment and Vitamin D Responder Classification

Baseline vitamin D status was determined from an intake visit D25 (standard of care for all patients seen at CTCA MRMC prior to initial consultation). Vitamin D deficiency was defined as a baseline D25 < 30 ng/mL. Patients who were vitamin D-deficient at baseline received vitamin D supplementation (most commonly D3, but if patient preferred D2 it was allowed, and generally USP certified brands were preferred) as part of routine clinical care through consultation with a naturopath (also standard of care) and the medical oncology team.

Although a formal protocol for replacement was not defined by the institution, starting replacement doses ranged from 2000 to 10,000 IU/d D3 and were adjusted accordingly based on subsequent D25 measurements.

The D25 assay was done in-house utilizing the Roche Cobas 6000 vitamin D total assay, an automated chemiluminescent immunoassay. The system employs VDBP labeled with a ruthenium complex as capture protein to bind 25-hydroxyvitamin D3 and D2. Cross-reactivity to 24,25-dihydroxyvitamin D is blocked by a specific monoclonal antibody.

The primary exposure of interest was response to vitamin D supplementation. Among patients with baseline vitamin D deficiency, a response was determined from the mean D25 concentration measured after the intake assessment through the end of the first year (to mirror the typical duration of HER2-targeted therapy). Patients were classified as responders if the mean follow-up D25 level was ≥30 ng/mL and as non-responders if the mean D25 remained <30 ng/mL. Responders were further stratified into low (30 to 40 ng/mL), medium (40 to 50 ng/mL), and high (>50 ng/mL) responder categories.

2.3. Outcomes

The primary outcome was disease-free survival (DFS). DFS was defined as the interval from the date of initiation of neoadjuvant therapy or definitive surgery, whichever occurred first, to the earliest documented disease recurrence, development of metastatic disease, or death from any cause. Patients without disease progression were censored at the date of last clinical follow-up.

2.4. Covariates

Clinical and pathologic covariates of interest included age at diagnosis, body mass index (BMI), estrogen receptor (ER) status, progesterone receptor (PR) status, tumor size, number of metastatic lymph nodes, presence of lymphovascular invasion, type of chemotherapy (neoadjuvant vs. adjuvant), use of pertuzumab, type of definitive surgery, and receipt of radiation therapy.

2.5. Statistical Analysis

Baseline patient characteristics were summarized using frequencies and percentages for categorical variables and appropriate measures of central tendency for continuous variables. Differences across groups were assessed using standard comparative statistical methods, as appropriate.

DFS was estimated using the Kaplan: Meier method, and survival curves were compared using the log-rank test. Univariate Cox proportional hazards regression models were first used to assess the association between individual covariates and DFS. Variables demonstrating clinical or statistical relevance were subsequently included in multivariable Cox proportional hazards models to evaluate independent associations after adjustment for potential confounders. Effect estimates were reported as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs).

The proportional hazards assumption was evaluated using both graphical methods, including log-minus-log plots for categorical variables, and statistical testing through extended Cox models incorporating time-dependent covariates for continuous variables. A two-sided p-value ≤ 0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics, version 28.0 (IBM Corp., Armonk, NY, USA).

3. Results

3.1. Study Cohort and Baseline Characteristics

A total of 196 patients met the initial eligibility criteria and were then subcategorized into vitamin D sufficiency or deficiency status at baseline. Baseline demographic and clinicopathologic characteristics are summarized in Table 1. Of the 196 patients eligible for analysis, 129 patients (65.8%) had deficient D25 levels (<30 ng/mL), while 67 patients (34.2%) had sufficient levels (≥30 ng/mL).

Nearly half of the patients had a body mass index (BMI) > 30 kg/m2 (44.9%). Most patients were White (66.3%), followed by African American (21.4%) and Hispanic (7.7%). Most tumors measured <2 cm (64.1%), and 55.7% of patients had no metastatic lymph node involvement. Lymphovascular invasion was present in 36.2% of cases.

Hormone receptor positivity was common, with estrogen receptor (ER) positivity in 70.5% and progesterone receptor (PR) positivity in 53.4% of patients. Approximately half of the cohort received neoadjuvant chemotherapy (49.5%), while the rest received adjuvant chemotherapy (50.5%). Definitive surgery consisted predominantly of mastectomy (56.9%), and most patients received adjuvant radiation therapy (73.5%). Pertuzumab was used in 50% of patients.

3.2. Baseline Vitamin D Status and Response to Supplementation

Among the 129 patients who were vitamin D-deficient at baseline, 76 patients (60.3%) achieved adequate vitamin D repletion (defined by mean D25 > 30 ng/mL in the first year of follow-up) and were classified as responders, while 50 patients (39.7%) remained below the target threshold and were classified as non-responders. Vitamin D response status could not be determined for three patients due to incomplete follow-up laboratory data and were not included for analysis. Among the 76 responders, 27 patients were classified as low responders (mean follow-up D25 level 30 to 40 ng/mL), 31 medium responders (40 to 50 ng/mL), and 18 high responders (>50 ng/mL).

3.3. Disease-Free Survival in the Overall Cohort

During follow-up, 31 of 196 patients (15.8%) experienced a disease-free survival (DFS) event. No deaths were recorded, so overall survival analysis was not possible, and in essence, DFS in this cohort would be accurately reframed as recurrence-free survival (RFS). Owing to the relatively low number of disease recurrence events, the median DFS was not reached. The mean DFS for the overall cohort was 10.2 years (95% confidence interval [CI], 9.58 to 10.83). The estimated 3-year DFS rate for the entire cohort was 88%, with non-responders having an 85% 3 yr DFS and responders having a 90% 3 yr DFS, as shown in Figure 2A.

In Figure 2B, an apparent “dose response” separation of the curves can be seen for those who were non-responders, and low, medium, and high responders to vitamin D replacement therapy, with the best outcomes associated with those who achieved mean D25 > 50 ng/mL.

3.4. Cox Proportional Hazards Analysis

Univariate and multivariable Cox proportional hazards regression analyses were performed to identify factors associated with DFS. See Table 2 for Univariate Cox Proportional Hazard Analysis. In univariate analyses, BMI, lymphovascular invasion, treatment sequence, and pertuzumab use were significantly associated with DFS. Patients with BMI ≥ 30 kg/m2 surprisingly demonstrated a lower hazard of disease progression compared with those with BMI < 30 kg/m2 (HR 0.41 p = 0.03). The presence of lymphovascular invasion was associated with a higher hazard of disease progression (HR 2.30, p = 0.04).

Patients treated in the neoadjuvant setting versus adjuvant (only) exhibited a higher hazard of disease progression (HR 3.80 p = 0.001) as well as those who received pertuzumab (HR 2.50 p = 0.02), likely due to selection bias of more advanced stage presentations.

DFS did not differ significantly by age at diagnosis, i.e., ≥50 years versus < 50 (HR 1.1 p = 0.7), race, i.e., non-White subjects versus White subjects (HR 1.3, p = 0.3), tumor size, i.e., ≥2 cm vs. <2 cm (HR 1.3 p = 0.3), nodal status, i.e., ≥1 metastatic versus 0 lymph nodes (HR 1.4 p = 0.3), estrogen receptor status, i.e., positive versus negative (HR 0.79 p = 0.5), progesterone receptor status, i.e., positive versus negative (HR 0.81 p = 0.6), nor baseline vitamin D25 status, i.e., <30 ng/mL versus > 30 ng/mL (HR 0.76 p = 0.45).

Although a binary analysis of White vs. non-White ethnicity was not significant, African Americans continued to have the worst 3 yr DFS of 79%, compared to 89% for White subjects and 100% for Hispanics.

When using vitamin D responders as reference, vitamin D non-responders had a HR of 1.7 for worse DFS, although the p-value was not significant p = 0.23.

Multivariable Cox proportional hazards regression (Table 3) was subsequently performed to evaluate independent associations with DFS after adjustment for BMI, lymphovascular invasion, treatment sequence, and pertuzumab use. In the adjusted model, lymphovascular invasion remained independently associated with worse DFS (HR 2.3 p = 0.05). Treatment sequence also remained independently associated with DFS, with neoadjuvant therapy associated with a higher hazard of disease progression compared with adjuvant therapy (HR 4.0 p = 0.008). After adjustment, BMI ≥ 30 kg/m2 continued to demonstrate a sizable lower hazard of disease progression compared with BMI < 30 kg/m2 with HR 0.46; however, it lost its statistical significance (p = 0.09).

Pertuzumab use was not independently associated with DFS (HR 1.20 p = 0.69).

4. Discussion

This is the first retrospective interventional cohort focused on women with HER2+ breast cancer with baseline and serial D25 measurements where all patients were given replacement therapy if deficient and doses were adjusted over time based on follow-up D25. The results suggest that not successfully fixing the vitamin D deficiency with appropriate vitamin D dosing could lead to a 70% higher risk of recurrence in patients with HER2+ breast cancer, although the confidence of this conclusion is weakened by the lack of statistical significance.

Because this cohort is not a retrospective observational cohort, but a retrospective interventional study (although not wholly accurate, we would call this a retrospective implementation study), the documentation of dose response (D25) correlation to improved DFS provides a fidelity component to this data that does not prove causation, but does provide a stronger clinical signal than a purely retrospective observational cohort that achieved statistical significance. Larger prospective “implementation studies” are warranted now for more definitive evidence.

In a previously reported single-institution observational cohort of patients treated with trastuzumab-based chemotherapy for localized HER2+ breast cancer, vitamin D intake (mean 10,472 IU/week) was associated with a HR of 0.36 (p = 0.03) after multivariate analysis [17]; however, a major weakness of the study was the lack of routine D25 intake measurements and follow-up, so analysis based on D25 levels achieved was not possible.

Another reason for publishing these findings are two recent randomized controlled trials showing a doubling of pCR in patients undergoing neoadjuvant chemotherapy for breast cancer [12,13], with benefit mainly seen in the HER2+ and triple-negative subtypes.

In the Omodei study (n = 80) [12], patients received 2000 IU/d of D3 versus placebo, and mean baseline D25 was 19.6 and 21.0 ng/mL in the vitamin D and placebo groups respectively, with confirmed difference in D25 levels at end of study 28.0 vs. 20.2 ng/mL. The pCR rate was 43% vs. 24% p = 0.04. When comparing those who achieved pCR versus those who did not, there was a higher prevalence of HER2+ and triple-negative subtypes (16% vs. 6%, and 40% vs. 18%, p = 0.02, respectively).

In the Özkurt 2025 study (n = 227) [13], patients were randomized to either D3 50,000 IU/week or no vitamin D supplementation. Similarly, patients were vitamin D-deficient at baseline 23 ng/mL in both arms, and 57% (average 71 ng/mL) achieved sufficiency in the intervention arm versus 18.4% in the control. The pCR rate was 24.3% versus 10.6% p = 0.012. In subset analysis, the pCR benefit was mainly seen in the HER2+ and triple-negative subtypes compared to ER+ subtypes (p = 0.016 and p = 0.004, respectively).

4.1. Limitations and Additional Strengths

Some of the limitations of this study include it being retrospective, single-institution, and likely underpowered. The underpowering due to low frequency of DFS events is likely multifactorial. First, it is unusual to have a HER2+ breast cancer cohort where nearly two-thirds of the tumors are <2.0 cm. Second, the majority of the HER2+ breast cancer cases were not of the ER-HER2+ subtype (70.5% were ER+). We still included this subset because, unlike the neoadjuvant studies above, our study period was not limited to neoadjuvant therapy and was inclusive of adjuvant therapy when patients were receiving antiestrogen therapy with trastuzumab +/− pertuzumab.

However, ER+HER2+ breast cancer has a better prognosis than ER-HER2+ breast cancer and has outcomes approaching luminal tumors [18]. This underpowering increases the risk that these findings were by chance.

Other study weaknesses include the study definition of exposure and the requirement of follow-up of D25 levels in the subsequent year without specification of the intervals for testing D25 and without a more specified standardized replacement protocol based on BMI. For example, patients who were “responders” might have been generally more compliant with conventional therapy and had better prognosis as a result and “non-responders” might have had overlap with socioeconomic difficulties as a confounder, had less frequent D25 tests done and had less efficient dose adjustments over the first year.

Lack of sufficient doses given to high BMI patients also likely underpowered the study. Vitamin D replacement treatment heterogeneity based on different clinician preferences might have created additional confounding variables.

Since we included both patients receiving neoadjuvant therapy and patients receiving adjuvant therapy, we did introduce more conventional treatment heterogeneity and our multivariate analysis did show that those who received neoadjuvant chemotherapy had a 4-fold worse prognosis (p = 0.008) due to selection of more advanced stages, and pertuzumab use nearly was significant (p = 0.07), as pertuzumab is indicated in patients with more advanced stages. These additional confounders also limit the generalizability of the findings.

Lastly, although none of the patients in this cohort had renal failure or were on dialysis, a formal assessment and categorization of renal insufficiency was not performed, which theoretically could have influenced results, since in such patients D25 levels might not have accurately reflected bioactive vitamin D due to impaired activation of D25 in the renal tubules.

A strength is that the patient population queried was more diverse and representative of a typical American population compared to those enrolled in previous RCTs, with a greater proportion of obese patients (44.9% > 30 kg/m2) and ethnic minorities, including African Americans (21.4%) and Hispanics (7.7%).

4.2. On the Role of BMI

A surprising finding in our cohort was that a high BMI emerged as a favorable prognostic factor. Although not statistically significant in multivariate analysis, the HR for disease recurrence for high BMI patients > 30 kg/m2 was 0.46, which is contrary to what was expected based on previous publications associating high BMI with worse outcomes in curative intent treatment of ER-HER2+ breast cancer [19,20] in the post-trastuzumab era, and in the pre-trastuzumab era [21].

It is our hypothesis that this reversal in the fortunes of high BMI patients could represent a clinical signal that a high BMI in part is a negative prognostic factor in HER2+ breast cancer through the mechanism of serving as a “vitamin D physiological trap” [22,23,24]. Vitamin 1,25(OH)D has also been shown to inhibit leptin and IL-6 production by adipocytes [25,26]. It is possible that a high BMI in this cohort selected out patients who were more likely to benefit from a D25-guided replacement therapy approach where patients required doses as high as 25,000 IU/d to achieve normal levels.

4.3. Review of Putative Mechanisms of Vitamin D Bioactivity in HER2+ Breast Cancer

Although our study did not query molecular insights into the reason for potential biological activity, it is important to review the large evidence base supporting the biological plausibility of such activity.

Vitamin D is a steroid prohormone and requires sequential hydroxylation to become biologically active, with both renal and extrarenal tissues, including breast epithelium, capable of activating circulating 25-hydroxyvitamin D to 1,25-hydroxyvitamin D or calcitriol [27]. Calcitriol signaling through the vitamin D receptor (VDR) influences multiple cancer-relevant pathways, including the inhibition of cellular proliferation via cell-cycle arrest, the induction of apoptosis through the modulation of Bcl-2 family proteins, the inhibition of matrix metalloproteinases involved in tumor progression, the downregulation of COX-2 expression and associated inflammation, and the suppression of additional invasive and angiogenic processes [6,27].

Recent evidence shows that vitamin D stimulation of intestinal VDR induces an improved microbiome and subsequent anti-tumor immunity in mouse models [28].

Vitamin D has been shown to enhance NK cell activity, providing a mechanism by which vitamin D might be particularly beneficial in HER2+ breast cancer treated in the post-trastuzumab era [29]. Preclinical models looking at another monoclonal antibody rituximab for lymphoma identified that maximal NK cell activity was observed at 65 ng/mL, supporting our findings that high responders, D25 levels > 50 ng/mL, had the best nominal DFS. Preclinical studies suggest vitamin D analogs may inhibit HER2-associated downstream signaling pathways, including the ERK and PI3K/AKT cascades [30,31]

Another potential mechanism for the biological activity of vitamin D in HER2+ breast cancer (and ER: breast cancer) is the known cross-talk between TP53 and VDR [32]. HER2+ breast cancer has a high prevalence of TP53 mutations, 55 to 75% [33], and patients with germline TP53 mutations are more likely to develop HER2+ breast cancer (67%) versus other subtypes [34]. In a subset analysis of TP53 mutated gastrointestinal cancers (using p53 immunoreactivity as a proxy) in the AMATERASU study [35], vitamin D supplementation led to 81% 5-year relapse free survival versus 31% in the placebo group (HR 0.27 95% CI 0.11 to 0.61), suggesting TP53 mutations might be an important biomarker for cancers more likely to benefit from vitamin D supplementation [36].

5. Conclusions

The inefficiency of vitamin D repletion (60.3% success rate) in our cohort emphasizes that a fixed dose replacement strategy, even with adjustments based on serial D25 measurements, does not reliably translate into adequate repletion in real-world practice, particularly for high BMI patients [37,38,39]. To resolve this underpowering issue in future prospective studies, it would be prudent for future clinical trials to focus on interventions utilizing scientifically proven dosing formulas based on patient weight and baseline D25 [40].

As of 2026, it is currently not in the ASCO guidelines to screen and address a vitamin D deficiency in patients newly diagnosed with cancer unless they are about to start a bone weakening agent [41]; however, it is NCCN guideline-supported to screen for and treat any nutritional deficiencies concurrent with cancer treatment [42].

A total of 70.3% of Americans have a vitamin D deficiency (<30 ng/mL) [43]. Of note, our study cohort had a similar prevalence of 65.8%. Given the high pretest odds, particularly for African Americans (94.5%) and Hispanics (86.5%) and obese individuals (80.1%) [43], and that vitamin D deficiency is commonly associated with quality-of-life issues, particularly fatigue [44,45,46], routine screening and replacement therapy should be standard of care.

A total of 43% of patients newly diagnosed with cancer report fatigue before even starting their conventional anti-cancer therapies [47], and fatigue is a bidirectional predictor of poor lifestyle choices and willingness to engage with exercise or nutritional interventions [48,49,50,51]. The clinical evidence suggests that unresolved pre-treatment fatigue predicts a >3-fold risk of having more severe post-treatment fatigue [52,53], yet fatigue due to a vitamin D deficiency is one of the easiest causes of fatigue to treat [44,45,46].

One of the mechanisms of fatigue amelioration from vitamin D is enhanced skeletal muscle mitochondrial function [54,55,56]. Of note, many patients who were treated for vitamin D deficiency in our cohort only recognized their chronic fatigue symptoms after experiencing the energy improvement with their replacement therapy, as many had adapted to the deficient state for decades.

Lastly, vitamin D sufficiency likely has a protective effect on some of the toxicities associated with chemotherapy, such as paclitaxel-associated neuropathy [57,58], risk of diabetes [59,60] and impaired cognitive function [61,62,63]. Vitamin D replacement therapy is extremely well tolerated, with most experts agreeing that risk of hypercalcemia in healthy children and adults is negligible with D25 levels < 100 ng/mL [64,65,66].

Given the current state of clinical evidence, the biological plausibility of vitamin D having anti-cancer effects in ER: and HER2+ breast cancer, and the convincing evidence base that it promotes wellness and improves quality of life, it should be standard of care, until RCT evidence suggests otherwise, to screen for and treat a vitamin D deficiency in all patients with breast cancer, particularly the ER: and HER2+ subtypes. That said, prospective implementation studies are needed to verify risk/benefit in the various breast cancer subtypes, and in the context of a stressful diagnosis of breast cancer, query whether fatigue can significantly be improved with vitamin D replacement therapy and lead to better odds of healthy lifestyle changes.

Acknowledgments

Digant Gupta provided statistical analysis, generated the Kaplan: Meier figures, and wrote the statistics section of the manuscript but was unable to review the final manuscript.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

E.R.A. designed the study, collected and analyzed the data, and wrote most of the manuscript. N.I. assisted in writing the manuscript and drafted several sections. S.B.C. contributed greatly to data extraction from the charts. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of CTCA MRMC in December 2016 with Protocol # MZ2017002_Vit D, approval date 1 December 2016.

Informed Consent Statement

Patient consent was waived due to this being a retrospective chart review without the use of personal identifying information.

Data Availability Statement

De-identified data is stored in two separate locations with access currently limited to current City of Hope Chicago (formerly CTCA MRMC) staff and faculty.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ERestrogen receptorPRprogesterone receptorHER2human epidermal growth factor receptor 2D25serum 25-hydroxyvitamin DRCTsrandomized controlled trialspCRpathological complete responseDFSdisease-free survivalCTCA MRMCCancer Treatment Centers of America Midwestern Regional Medical CenterIRBinstitutional review boardBMIbody mass indexHRhazard ratioCIconfidence intervalNKnatural killerVDRvitamin D receptorIHCimmunohistochemistryFISHfluorescent in situ hybridizationVDBPvitamin D-binding protein

References

1. American Cancer Society Breast Cancer Statistics 2026 Available online: https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html(accessed on 9 March 2026)
2. Gradishar W.J. Moran M.S. Abraham J. Abramson V. Aft R. Agnese D. Allison K.H. Anderson B. Bailey J. Burstein H.J. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology J. Natl. Compr. Cancer Netw. 2024 22 331 357 10.6004/jnccn.2024.0035 39019058
3. Norman A.W. The History of the Discovery of Vitamin D and Its Daughter Steroid Hormone Ann. Nutr. Metab. 2012 61 199 206 10.1159/000343104 23183289
4. Christakos S. Dhawan P. Verstuyf A. Verlinden L. Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects Physiol. Rev. 2016 96 365 408 10.1152/physrev.00014.2015 26681795 PMC4839493
5. Elder C.J. Bishop N.J. Rickets Lancet 2014 383 1665 1676 10.1016/S0140-6736(13)61650-5 24412049
6. Jeon S.M. Shin E.A. Exploring vitamin D metabolism and function in cancer Exp. Mol. Med. 2018 50 1 14 10.1038/s12276-018-0038-9 29657326 PMC5938036
7. Yao S. Sucheston L.E. Millen A.E. Johnson C.S. Trump D.L. Nesline M.K. Davis W. Hong C.C. McCann S.E. Hwang H. Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study PLoS ONE 2011 6 e17251 10.1371/journal.pone.0017251 21386992 PMC3046139
8. Lope V. Castelló A. Mena-Bravo A. Amiano P. Aragonés N. Fernández-Villa T. Guevara M. Dierssen-Sotos T. Fernandez-Tardón G. Castaño-Vinyals G. Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC-Spain) J. Steroid Biochem. Mol. Biol. 2018 182 4 13 10.1016/j.jsbmb.2018.04.005 29679754
9. Visvanathan K. Mondul A.M. Zeleniuch-Jacquotte A. Wang M. Gail M.H. Yaun S.S. Weinstein S.J. McCullough M.L. Eliassen A.H. Cook N.R. Circulating vitamin D and breast cancer risk: An international pooling project of 17 cohorts Eur. J. Epidemiol. 2023 38 11 29 10.1007/s10654-022-00921-1 36593337 PMC10039648
10. Schöttker B. Jorde R. Peasey A. Thorand B. Jansen E.H. De Groot L. Streppel M. Gardiner J. Ordóñez-Mena J.M. Perna L. Vitamin D and mortality: Meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States BMJ 2014 348 g3656 10.1136/bmj.g3656 24938302 PMC4061380
11. Kuznia S. Zhu A. Akutsu T. Buring J.E. Camargo C.A. Jr. Cook N.R. Chen L.J. Cheng T.Y.D. Hantunen S. Lee I.M. Efficacy of vitamin D3 supplementation on cancer mortality: Systematic review and individual patient data meta-analysis of randomised controlled trials Ageing Res. Rev. 2023 87 101923 10.1016/j.arr.2023.101923 37004841 PMC10214278
12. Omodei M.S. Chimicoviaki J. Buttros D.A.B. Almeida-Filho B.S. Carvalho-Pessoa C.P. Carvalho-Pessoa E. Vespoli H.D.L. Nahas E.A.P. Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial Nutr. Cancer 2025 77 648 657 10.1080/01635581.2025.2480854 40098326
13. Özkurt E. Ordu C. Özmen T. Ilgun A.S. Soybir G. Celebi F. Koç E. Ak N. Alco G. Kurt S. Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial World J. Surg. 2025 49 1396 1405 10.1002/wjs.12587 40229998 PMC12134193
14. Tirgar A. Rezaei M. Ehsani M. Salmani Z. Rastegari A. Jafari E. Khandani B.K. Nakhaee N. Khaksari M. Moazed V. Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: A pilot randomized clinical trial Sci. Rep. 2024 14 21372 10.1038/s41598-024-72172-x 39266591 PMC11393349
15. Von Minckwitz G. Untch M. Blohmer J.U. Costa S.D. Eidtmann H. Fasching P.A. Gerber B. Eiermann W. Hilfrich J. Huober J. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes J. Clin. Oncol. 2012 30 1796 1804 10.1200/JCO.2011.38.8595 22508812
16. Spring L.M. Fell G. Arfe A. Sharma C. Greenup R. Reynolds K.L. Smith B.L. Alexander B. Moy B. Isakoff S.J. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis Clin. Cancer Res. 2020 26 2838 2848 10.1158/1078-0432.CCR-19-3492 32046998 PMC7299787
17. Zeichner S.B. Koru-Sengul T. Shah N. Liu Q. Markward N.J. Montero A.J. Glück S. Silva O. Ahn E.R. Improved Clinical Outcomes Associated with Vitamin D Supplementation During Adjuvant Chemotherapy in Patients with HER2+ Nonmetastatic Breast Cancer Clin. Breast Cancer 2015 15 e1 e11 10.1016/j.clbc.2014.08.001 25241299
18. Debien V. de Azambuja E. Piccart-Gebhart M. Optimizing treatment for HER2-positive HR-positive breast cancer Cancer Treat. Rev. 2023 115 102529 10.1016/j.ctrv.2023.102529 36921556
19. Cantini L. Pistelli M. Merloni F. Fontana A. Bertolini I. De Angelis C. Bastianelli L. Della Mora A. Santinelli A. Savini A. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients Clin. Breast Cancer 2020 20 e89: 98 10.1016/j.clbc.2019.06.008 31378534
20. Ligorio F. Zambelli L. Bottiglieri A. Castagnoli L. Zattarin E. Lobefaro R. Ottini A. Vingiani A. Pupa S.M. Bianchi G.V. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients Ther. Adv. Med. Oncol. 2021 13 17588359211006960 10.1177/17588359211006960 33948122 PMC8053837
21. Mazzarella L. Disalvatore D. Bagnardi V. Rotmensz N. Galbiati D. Caputo S. Curigliano G. Pelicci P.G. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients Eur. J. Cancer 2013 49 3588 3597 10.1016/j.ejca.2013.07.016 23953055
22. Di Nisio A. De Toni L. Sabovic I. Rocca M.S. De Filippis V. Opocher G. Azzena B. Vettor R. Plebani M. Foresta C. Impaired Release of Vitamin D in Dysfunctional Adipose Tissue: New Cues on Vitamin D Supplementation in Obesity J. Clin. Endocrinol. Metab. 2017 102 2564 2574 10.1210/jc.2016-3591 28187222
23. Park C.Y. Shin Y. Kim J.H. Zhu S. Jung Y.S. Han S.N. Effects of high fat diet-induced obesity on vitamin D metabolism and tissue distribution in vitamin D deficient or supplemented mice Nutr. Metab. 2020 17 44 10.1186/s12986-020-00463-x PMC7294642 32549901
24. Uçar N. Pickering R.T. Mueller P.M. Deeney J.T. Morales Suárez-Varela M. Soriano J.M. Holick M.F. Vitamin D3, 25-Hydroxyvitamin D3, and 1,25-Dihydroxyvitamin D3 Uptake in Cultured Human Mature Adipocytes Nutrients 2025 17 2107 10.3390/nu17132107 40647210 PMC12251007
25. Nimitphong H. Guo W. Holick M.F. Fried S.K. Lee M. Vitamin D Inhibits Adipokine Production and Inflammatory Signaling Through the Vitamin D Receptor in Human Adipocytes Obesity 2021 29 562 568 10.1002/oby.23109 33624437
26. Mutt S.J. Karhu T. Lehtonen S. Lehenkari P. Carlberg C. Saarnio J. Sebert S. Hyppoenen E. Järvelin M.R. Herzig K.H. Inhibition of cytokine secretion from adipocytes by 1,25-dihydroxyvitamin D3 via the NF-κB pathway FASEB J. 2012 26 4400 4407 10.1096/fj.12-210880 22798425
27. Welsh J. Function of the vitamin D endocrine system in mammary gland and breast cancer Mol. Cell. Endocrinol. 2017 453 88 95 10.1016/j.mce.2017.04.026 28579119 PMC5538720
28. Giampazolias E. Pereira da Costa M. Lam K.C. Lim K.H.J. Cardoso A. Piot C. Chakravarty P. Blasche S. Patel S. Biram A. Vitamin D regulates microbiome-dependent cancer immunity Science 2024 384 428 437 10.1126/science.adh7954 38662827 PMC7615937
29. Christofyllakis K. Neumann F. Bewarder M. Thurner L. Kaddu-Mulindwa D. Kos I.A. Lesan V. Bittenbring J.T. Vitamin D Enhances Immune Effector Pathways of NK Cells Thus Providing a Mechanistic Explanation for the Increased Effectiveness of Therapeutic Monoclonal Antibodies Nutrients 2023 15 3498 10.3390/nu15163498 37630689 PMC10457932
30. Lee H.J. So J.Y. DeCastro A. Smolarek A. Paul S. Maehr H. Uskokovic M. Suh N. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling J. Steroid Biochem. Mol. Biol. 2010 121 408 412 10.1016/j.jsbmb.2010.03.053 20304052 PMC2906695
31. So J.Y. Wahler J.E. Yoon T. Smolarek A.K. Lin Y. Shih W.J. Maehr H. Uskokovic M. Liby K.T. Sporn M.B. Oral Administration of a Gemini Vitamin D Analog, a Synthetic Triterpenoid and the Combination Prevents Mammary Tumorigenesis Driven by ErbB2 Overexpression Cancer Prev. Res. 2013 6 959 970 10.1158/1940-6207.CAPR-13-0087 PMC3767182 23856074
32. Reichrath J. Reichrath S. Vogt T. Römer K. Crosstalk Between Vitamin D and p53 Signaling in Cancer: An Update Sunlight, Vitamin D and Skin Cancer SpringerBerlin/Heidelberg, Germany2020 307 318 10.1007/978-3-030-46227-7_15 32918225
33. Silwal-Pandit L. Vollan H.K.M. Chin S.F. Rueda O.M. McKinney S. Osako T. Quigley D.A. Kristensen V.N. Aparicio S. Børresen-Dale A.L. TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance Clin. Cancer Res. 2014 20 3569 3580 10.1158/1078-0432.CCR-13-2943 24803582
34. Melhem-Bertrandt A. Bojadzieva J. Ready K.J. Obeid E. Liu D.D. Gutierrez-Barrera A.M. Litton J.K. Olopade O.I. Hortobagyi G.N. Strong L.C. Early onset HER2-positive breast cancer is associated with germline TP53 mutations Cancer 2012 118 908 913 10.1002/cncr.26377 21761402 PMC3527897
35. Kanno K. Akutsu T. Ohdaira H. Suzuki Y. Urashima M. Effect of Vitamin D Supplements on Relapse or Death in a p53-Immunoreactive Subgroup with Digestive Tract Cancer JAMA Netw. Open 2023 6 e2328886 10.1001/jamanetworkopen.2023.28886 37606927 PMC10445201
36. Holick M.F. The Death D-Fying Vitamin D3 for Digestive Tract Cancers: The p53 Antibody Connection JAMA Netw. Open 2023 6 e2328883 10.1001/jamanetworkopen.2023.28883 37606930
37. Wimalawansa S.J. Vitamin D’s Impact on Cancer Incidence and Mortality: A Systematic Review Nutrients 2025 17 2333 10.3390/nu17142333 40732958 PMC12298439
38. Lee P. Greenfield J.R. Seibel M.J. Eisman J.A. Center J.R. Adequacy of Vitamin D Replacement in Severe Deficiency Is Dependent on Body Mass Index Am. J. Med. 2009 122 1056 1060 10.1016/j.amjmed.2009.06.008 19854337
39. Jorde R. Sneve M. Emaus N. Figenschau Y. Grimnes G. Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: The Tromsø study Eur. J. Nutr. 2010 49 401 407 10.1007/s00394-010-0098-7 20204652
40. van Groningen L. Opdenoordt S. van Sorge A. Telting D. Giesen A. de Boer H. Cholecalciferol loading dose guideline for vitamin D-deficient adults Eur. J. Endocrinol. 2010 162 805 811 10.1530/EJE-09-0932 20139241
41. Shapiro C.L. Van Poznak C. Lacchetti C. Kirshner J. Eastell R. Gagel R. Smith S. Edwards B.J. Frank E. Lyman G.H. Management of Osteoporosis in Survivors of Adult Cancers with Nonmetastatic Disease: ASCO Clinical Practice Guideline J. Clin. Oncol. 2019 37 2916 2946 10.1200/JCO.19.01696 31532726
42. NCCN Survivorship 2026 Available online: https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf(accessed on 9 March 2026)
43. Liu X. Baylin A. Levy P.D. Vitamin D deficiency and insufficiency among US adults: Prevalence, predictors and clinical implications Br. J. Nutr. 2018 119 928 936 10.1017/S0007114518000491 29644951
44. Roy S. Sherman A. Monari-Sparks M.J. Schweiker O. Hunter K. Correction of low vitamin D improves fatigue: Effect of correction of low vitamin D in fatigue study (EViDiF study) N. Am. J. Med. Sci. 2014 6 396 402 10.4103/1947-2714.139291 25210673 PMC4158648
45. Nowak A. Boesch L. Andres E. Battegay E. Hornemann T. Schmid C. Bischoff-Ferrari H.A. Suter P.M. Krayenbuehl P.A. Effect of vitamin D3 on self-perceived fatigue A double-blind randomized placebo-controlled trial Medicine 2016 95 e5353 10.1097/MD.0000000000005353 28033244 PMC5207540
46. Frankling M. Klasson C. Sandberg C. Nordstrom M. Warnqvist A. Bergqvist J. Bergman P. Bjorkhem-Bergman L. ‘Palliative D’: Vitamin D Supplementation to Palliative Care Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial Cancers 2021 13 3707 10.3390/cancers13153707 34359609 PMC8345220
47. Kang Y.E. Yoon J.H. Park Nhyun Ahn Y.C. Lee E.J. Son C.G. Prevalence of cancer-related fatigue based on severity: A systematic review and meta-analysis Sci. Rep. 2023 13 12815 10.1038/s41598-023-39046-0 37550326 PMC10406927
48. Puetz T.W. Herring M.P. Differential Effects of Exercise on Cancer-Related Fatigue During and Following Treatment Am. J. Prev. Med. 2012 43 e1 e24 10.1016/j.amepre.2012.04.027 22813691
49. Blaney J. Lowe-Strong A. Rankin J. Campbell A. Allen J. Gracey J. The Cancer Rehabilitation Journey: Barriers to and Facilitators of Exercise Among Patients with Cancer-Related Fatigue Phys. Ther. 2010 90 1135 1147 10.2522/ptj.20090278 20558566
50. Kim S. Han J. Lee M.Y. Jang M.K. The experience of cancer-related fatigue, exercise and exercise adherence among women breast cancer survivors: Insights from focus group interviews J. Clin. Nurs. 2020 29 758 769 10.1111/jocn.15114 31769562
51. Puklin L.S. Ferrucci L.M. Harrigan M. McGowan C. Zupa M. Cartmel B. Li F.Y. Ligibel J.A. Spiegelman D. Sharifi M. Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial Cancer 2024 130 2440 2452 10.1002/cncr.35280 38470431 PMC11214600
52. Di Meglio A. Havas J. Soldato D. Presti D. Martin E. Pistilli B. Menvielle G. Dumas A. Charles C. Everhard S. Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care J. Clin. Oncol. 2022 40 1111 1123 10.1200/JCO.21.01252 35061509 PMC8966972
53. Rosas J.C. Aguado-Barrera M.E. Azria D. Briers E. Elliott R. Farcy-Jacquet M.P. Giraldo A. Gutiérrez-Enríquez S. Rancati T. Rattay T. (Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer Int. J. Cancer 2023 153 1579 1591 10.1002/ijc.34640 37403702
54. Sinha A. Hollingsworth K.G. Ball S. Cheetham T. Improving the Vitamin D Status of Vitamin D Deficient Adults Is Associated with Improved Mitochondrial Oxidative Function in Skeletal Muscle J. Clin. Endocrinol. Metab. 2013 98 E509 E513 10.1210/jc.2012-3592 23393184
55. Ryan Z.C. Craig T.A. Folmes C.D. Wang X. Lanza I.R. Schaible N.S. Salisbury J.L. Nair K.S. Terzic A. Sieck G.C. 1α,25-Dihydroxyvitamin D3 Regulates Mitochondrial Oxygen Consumption and Dynamics in Human Skeletal Muscle Cells J. Biol. Chem. 2016 291 1514 1528 10.1074/jbc.M115.684399 26601949 PMC4714233
56. Ashcroft S.P. Bass J.J. Kazi A.A. Atherton P.J. Philp A. The vitamin D receptor regulates mitochondrial function in C2C12 myoblasts Am. J. Physiol. Cell Physiol. 2020 318 C536 C541 10.1152/ajpcell.00568.2019 31940245 PMC7099523
57. Jennaro T.S. Fang F. Kidwell K.M. Smith E.M.L. Vangipuram K. Burness M.L. Griggs J.J. Van Poznak C. Hayes D.F. Henry N.L. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy Breast Cancer Res. Treat. 2020 180 707 714 10.1007/s10549-020-05584-8 32166478 PMC7945004
58. Chen C.S. Zirpoli G. Barlow W.E. Budd G.T. McKiver B. Pusztai L. Hortobagyi G.N. Albain K.S. Damaj M.I. Godwin A.K. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221 J. Natl. Compr. Cancer Netw. 2023 21 1172 1180.e3 10.6004/jnccn.2023.7062 PMC10976748 37935109
59. Demay M.B. Pittas A.G. Bikle D.D. Diab D.L. Kiely M.E. Lazaretti-Castro M. Lips P. Mitchell D.M. Murad M.H. Powers S. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab. 2024 109 1907 1947 10.1210/clinem/dgae290 38828931
60. Pittas A.G. Kawahara T. Jorde R. Dawson-Hughes B. Vickery E.M. Angellotti E. Nelson J. Trikalinos T.A. Balk E.M. Vitamin D and Risk for Type 2 Diabetes in People with Prediabetes Ann. Intern. Med. 2023 176 355 363 10.7326/M22-3018 36745886
61. Zhang W. Liu Y. Pan Y. Jiang K. Vitamin D Ameliorates Doxorubicin-Induced Cognitive Dysfunction via Modulation of the SFRP1/β-Catenin Axis ACS Chem. Neurosci. 2025 16 4191 4202 10.1021/acschemneuro.5c00272 41139396
62. Chen W.Y. Cheng Y.C. Chiu C.C. Liu H.C. Huang M.C. Tu Y.K. Kuo P.H. Effects of Vitamin D Supplementation on Cognitive Outcomes: A Systematic Review and Meta-Analysis Neuropsychol. Rev. 2024 34 568 580 10.1007/s11065-023-09598-z 37418225
63. Cochar-Soares N. da Silva T.B.P. Luiz M.M. Tofani P.S. Delinocente M.L.B. de Oliveira Máximo R. Steptoe A. de Oliveira C. da Silva Alexandre T. Vitamin D deficiency as a risk factor for cognitive decline in individuals aged 50 or older Geroscience 2026 48 2491 2503 10.1007/s11357-025-01800-9 40690159 PMC12972389
64. Brustad N. Yousef S. Stokholm J. Bønnelykke K. Bisgaard H. Chawes B.L. Safety of High-Dose Vitamin D Supplementation Among Children Aged 0 to 6 Years JAMA Netw. Open 2022 5 e227410 10.1001/jamanetworkopen.2022.7410 35420658 PMC9011124
65. Zeng S. Chu C. Doebis C. von Baehr V. Hocher B. Reference values for free 25-hydroxy-vitamin D based on established total 25-hydroxy-vitamin D reference values J. Steroid Biochem. Mol. Biol. 2021 210 105877 10.1016/j.jsbmb.2021.105877 33741448
66. Holick M.F. Binkley N.C. Bischoff-Ferrari H.A. Gordon C.M. Hanley D.A. Heaney R.P. Murad M.H. Weaver C.M. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab. 2011 96 1911 1930 10.1210/jc.2011-0385 21646368
Figure 1

An overview of vitamin D metabolism. Vitamin D as an endogenous secosteroid with many effects on human health and cancer outcomes primarily through its interactions with vitamin D receptor (VDR) [6]. Pre-vitamin D3 is primarily converted to D3 in the skin with UV-B exposure, then hydroxylated by CYP2R1 or 25-hydroxylase in the liver to 25(OH)D, and lastly CYP27B1 or 1-alpha hydroxylase in the renal tubules to calcitriol or 1,25(OH)D. Vitamin D metabolites are stabilized in the serum by Vitamin D Binding Protein (VDBP).

The genomic effects of 1,25(OH)D occur through binding to VDR-RXR complexes which subsequently interact with Vitamin D Responsive Elements (VDRE) on DNA. Additionally, non-genomic effects can be mediated through interaction of 1,25(OH)D with membrane associated rapid response steroid (MARRS) receptor.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 2

(A) Kaplan: Meier DFS curves analyzed by vitamin D responders versus non-responders. (B) Kaplan: Meier DFS curves by tiers of vitamin D response versus non-responders, specifically low responders (30 to 40 ng/mL), medium responders (40 to 50 ng/mL) and high responders (>50 ng/mL).

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Baseline demographics and characteristics.

VariablesN (%)
Baseline Vitamin D
        <30 ng/mL129 (65.8)
        ≥30 ng/mL67 (34.2)
Age at diagnosis
        <50 years101 (51.5)
        ≥50 years95 (48.5)
BMI
        <30 kg/m2108 (55.1)
        ≥30 kg/m288 (44.9)
Race
        White130 (66.3)
        African American42 (21.4)
        Hispanic15 (7.7)
        Others9 (4.6)
Tumor size
        <2 cm123 (64.1)
        ≥2 cm69 (35.9)
        Unknown4
Number of metastatic lymph nodes
        0108 (55.7)
        ≥186 (44.3)
        Unknown2
Lymphovascular invasion
        No104 (63.8)
        Yes59 (36.2)
        Unknown33
ER status
        Negative56 (29.5)
        Positive134 (70.5)
        Unknown6
PR status
        Negative89 (46.6)
        Positive102 (53.4)
        Unknown5
Type of chemotherapy
        Neoadjuvant97 (49.5)
        Adjuvant99 (50.5)
Definitive Surgery
        Lumpectomy84 (43.1)
        Mastectomy111 (56.9)
        Unknown1
Radiation therapy
        No52 (26.5)
        Yes144 (73.5)
Pertuzumab
        No98 (50)
        Yes98 (50)
Disease progression
        No165 (84.2)
        Yes31 (15.8)
Vitamin D response after supplementation
        Responders76 (60.3)
        low27
        medium31
        high18
        Non-responders50 (39.7)
        Unknown3
Table 2

Univariate Cox proportional hazard analysis (* reflects statistical significance achieved).

VariablesHazard Ratio95% CIp-Value
Vitamin D response after supplementation
        Responders (reference)
        Non-responders1.70.71 to 4.30.23
Vitamin D response after supplementation
        High responders (reference)
        Medium responders1.40.26 to 7.80.69
        Low responders1.10.19 to 6.80.89
        Non-responders2.10.46 to 9.60.34
Baseline Vitamin D
        >=30 ng/mL (reference)
        <30 ng/mL0.760.37 to 1.60.45
Age at diagnosis
        <50 years (reference)
        >=50 years1.10.56 to 2.30.73
BMI
        <30 kg/m2 (reference)
        >=30 kg/m20.410.18 to 0.910.03 *
Race
        White (reference)
        Others1.30.62 to 2.60.50
Tumor size
        <2 cm (reference)
        >=2 cm1.30.64 to 2.80.44
Number of metastatic lymph nodes
        0 (reference)
        >=11.40.69 to 2.90.33
Lymphovascular invasion
        No (reference)
        Yes2.31.03 to 5.30.04 *
ER status
        Negative (reference)
        Positive0.790.37 to 1.70.53
PR status
        Negative (reference)
        Positive0.810.40 to 1.70.57
Type of chemotherapy
        Adjuvant (reference)
        Neoadjuvant3.81.7 to 8.70.001 *
Definitive Surgery
        Lumpectomy (reference)
        Mastectomy1.50.72 to 3.20.28
Radiation therapy
        No (reference)
        Yes1.40.58 to 3.50.44
Pertuzumab
        No (reference)
        Yes2.51.2 to 5.50.02 *
Nuclear grade
        1 or 2 (reference)
        31.40.59 to 3.50.43
Table 3

Multivariate Cox regression analysis (* reflects statistical significance achieved).

VariablesHazard Ratio95% CIp-Value
BMI
        <30 kg/m2 (reference)
        ≥30 kg/m20.460.18 to 1.10.09
Lymphovascular invasion
        No (reference)
        Yes2.31.01 to 5.40.05 *
Type of chemotherapy
        Adjuvant (reference)
        Neoadjuvant4.01.4 to 11.30.008 *
Pertuzumab
        No (reference)
        Yes1.20.45 to 3.40.07
Publication and source details

Original title: A Retrospective Interventional Study Examining Whether Successful Replacement Therapy After a Confirmed Vitamin D Deficiency Correlates with Improved Disease-Free Survival in the Curative Intent Treatment of HER2+ Breast Cancer

Eugene R. Ahn; Nandhini Iyer; Samuel B. Cothran

Nutrients · 2026

* Correspondence: eugene.ahn@lumc.edu© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T16:25:15.787965+00:00

DOI: 10.3390/nu18081253 · PMC13118711